Physician profile
Bashar Saour
NPI 1164872958
$605.16
in general payments reported to CMS, 2019-2025
14 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.13 · 2021: $25.13 · 2022: $41.40 · 2023: $69.29 · 2024: $255 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $158.20 | 2021-2024 | Daybue, Nuplazid |
| Ucb, INC. | $154.73 | 2022-2025 | Briviact, Nayzilam, Fintepla |
| Akcea Therapeutics, INC. | $87.13 | 2019 | |
| Sk Life Science, INC. | $35.13 | 2022-2024 | |
| Neurelis, INC. | $33.99 | 2023-2024 | Valtoco |
| Pfizer INC. | $28.71 | 2024-2025 | |
| Genentech USA, INC. | $24.16 | 2024 | Ocrevus |
| Merz Pharmaceuticals, LLC | $16.40 | 2025 | Xeomin, Inbrija |
| Amneal Pharmaceuticals LLC | $14.58 | 2023 | Rytary |
| Amylyx Pharmaceuticals, INC. | $14.39 | 2023 | Relyvrio |
| Otsuka America Pharmaceutical, INC. | $12.71 | 2023 | Nuedexta |
| Biogen, INC. | $12.54 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.49 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Saour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.